Carlos R Oliveira1, Robert M Rock2, Eugene D Shapiro3, Xiao Xu4, Lisbet Lundsberg4, Liye B Zhang5, Aileen Gariepy4, Jessica L Illuzzi4, Sangini S Sheth4. 1. Departments of Pediatrics and Medicine, School of Medicine, Yale University, New Haven. Electronic address: carlos.oliveira@yale.edu. 2. School of Medicine, Yale University, New Haven. 3. Departments of Pediatrics and Medicine, School of Medicine, Yale University, New Haven. 4. Department of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, Yale University, New Haven. 5. Frank H. Netter School of Medicine, Quinnipiac University, North Haven, CT.
Abstract
BACKGROUND: Despite the availability of a safe and efficacious vaccine against human papillomavirus, uptake of the vaccine in the United States is low. Missed clinical opportunities to recommend and to administer human papillomavirus vaccine are considered one of the most important reasons for its low uptake in adolescents; however, little is known about the frequency or characteristics of missed opportunities in the young adult (18-26 years of age) population. OBJECTIVE: The objective of the study was to assess both the rates of and the factors associated with missed opportunities for human papillomavirus immunization among young adult women who attended an urban obstetrics and gynecology clinic. STUDY DESIGN: In this cross-sectional study, medical records were reviewed for all women 18-26 years of age who were underimmunized (<3 doses) and who sought care from Feb. 1, 2013, to January 31, 2014, at an urban, hospital-based obstetrics and gynecology clinic. A missed opportunity for human papillomavirus immunization was defined as a clinic visit at which the patient was eligible to receive the vaccine and a dose was due but not administered. Multivariable logistic regression was used to test associations between sociodemographic variables and missed opportunities. RESULTS: There were 1670 vaccine-eligible visits by 1241 underimmunized women, with a mean of 1.3 missed opportunities/person. During the study period, 833 of the vaccine eligible women (67.1%) had at least 1 missed opportunity. Overall, the most common types of visits during which a missed opportunity occurred were postpartum visits (17%) or visits for either sexually transmitted disease screening (21%) or contraception (33%). Of the patients with a missed opportunity, 26.5% had a visit at which an injectable medication or a different vaccine was administered. Women who identified their race as black had higher adjusted odds of having a missed opportunity compared with white women (adjusted odds ratio, 1.61 [95% confidence interval, 1.08-2.41], P < .02). Women who reported a non-English- or non-Spanish-preferred language had lower adjusted odds of having a missed opportunity (adjusted odds ratio, 0.25 [95% confidence interval, 0.07-0.87], P = .03). No other patient characteristics assessed in this study were significantly associated with having a missed opportunity. CONCLUSION: A majority of young-adult women in this study had missed opportunities for human papillomavirus immunization, and significant racial disparity was observed. The greatest frequency of missed opportunities occurred with visits for either contraception or for sexually transmitted disease screening.
BACKGROUND: Despite the availability of a safe and efficacious vaccine against human papillomavirus, uptake of the vaccine in the United States is low. Missed clinical opportunities to recommend and to administer human papillomavirus vaccine are considered one of the most important reasons for its low uptake in adolescents; however, little is known about the frequency or characteristics of missed opportunities in the young adult (18-26 years of age) population. OBJECTIVE: The objective of the study was to assess both the rates of and the factors associated with missed opportunities for human papillomavirus immunization among young adult women who attended an urban obstetrics and gynecology clinic. STUDY DESIGN: In this cross-sectional study, medical records were reviewed for all women 18-26 years of age who were underimmunized (<3 doses) and who sought care from Feb. 1, 2013, to January 31, 2014, at an urban, hospital-based obstetrics and gynecology clinic. A missed opportunity for human papillomavirus immunization was defined as a clinic visit at which the patient was eligible to receive the vaccine and a dose was due but not administered. Multivariable logistic regression was used to test associations between sociodemographic variables and missed opportunities. RESULTS: There were 1670 vaccine-eligible visits by 1241 underimmunized women, with a mean of 1.3 missed opportunities/person. During the study period, 833 of the vaccine eligible women (67.1%) had at least 1 missed opportunity. Overall, the most common types of visits during which a missed opportunity occurred were postpartum visits (17%) or visits for either sexually transmitted disease screening (21%) or contraception (33%). Of the patients with a missed opportunity, 26.5% had a visit at which an injectable medication or a different vaccine was administered. Women who identified their race as black had higher adjusted odds of having a missed opportunity compared with white women (adjusted odds ratio, 1.61 [95% confidence interval, 1.08-2.41], P < .02). Women who reported a non-English- or non-Spanish-preferred language had lower adjusted odds of having a missed opportunity (adjusted odds ratio, 0.25 [95% confidence interval, 0.07-0.87], P = .03). No other patient characteristics assessed in this study were significantly associated with having a missed opportunity. CONCLUSION: A majority of young-adult women in this study had missed opportunities for human papillomavirus immunization, and significant racial disparity was observed. The greatest frequency of missed opportunities occurred with visits for either contraception or for sexually transmitted disease screening.
Authors: Jason D Wright; Shravya Govindappagari; Neha Pawar; Kirsten Cleary; William M Burke; Patricia C Devine; Yu-Shiang Lu; Wei-Yann Tsai; Sharyn N Lewin; Thomas J Herzog Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Abbey B Berenson; Mahbubur Rahman; Jacqueline M Hirth; Richard E Rupp; Kwabena O Sarpong Journal: Am J Obstet Gynecol Date: 2016-02-17 Impact factor: 8.661
Authors: Richard H Beigi; Kimberly B Fortner; Flor M Munoz; Jeff Roberts; Jennifer L Gordon; Htay Htay Han; Greg Glenn; Philip R Dormitzer; Xing Xing Gu; Jennifer S Read; Kathryn Edwards; Shital M Patel; Geeta K Swamy Journal: Clin Infect Dis Date: 2014-12-15 Impact factor: 9.079
Authors: Harrell W Chesson; Donatus U Ekwueme; Mona Saraiya; Meg Watson; Douglas R Lowy; Lauri E Markowitz Journal: Vaccine Date: 2012-08-04 Impact factor: 3.641
Authors: Walter W Williams; Peng-Jun Lu; Alissa O'Halloran; Carolyn B Bridges; David K Kim; Tamara Pilishvili; Craig M Hales; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2015-02-06 Impact factor: 17.586
Authors: Lane McLendon; Jesse Puckett; Chelsea Green; Jenna James; Katharine J Head; Hee Yun Lee; Jennifer Young Pierce; Mark Beasley; Casey L Daniel Journal: Hum Vaccin Immunother Date: 2020-12-16 Impact factor: 3.452
Authors: Lital Avni-Singer; Carlos R Oliveira; Ashlynn Torres; Eugene D Shapiro; Linda M Niccolai; Sangini S Sheth Journal: Obstet Gynecol Date: 2020-11 Impact factor: 7.623
Authors: Grace W Ryan; Sarah S Perry; Aaron Scherer; Mary E Charlton; Sato Ashida; Paul A Gilbert; Natoshia Askelson Journal: Vaccine X Date: 2022-07-09